Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ImmunityBio, Inc. (IBRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.9900+0.2700 (+7.26%)
At close: 04:00PM EDT
4.0500 +0.06 (+1.50%)
After hours: 06:14PM EDT
Advertisement

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
858 633 0300
https://immunitybio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees688

Key Executives

NameTitlePayExercisedYear Born
Dr. Patrick Soon-Shiong F.A.C.S., FACS, FRCS (C), M.Sc.Exec. Chairman, Global Chief Scientific & Medical Officer539.3kN/A1953
Mr. Richard Gerald AdcockPres, CEO & Director1.17MN/A1969
Mr. David C. SachsCFO, Principal Financial Officer & Principal Accounting Officer633.13kN/A1978
Dr. Leonard S. Sender M.D.Chief Operating OfficerN/AN/AN/A
Mr. Jason R. LiljestromGen. Counsel & Corp. Sec.N/AN/A1983
Ms. Sarah SingletonChief Communications OfficerN/AN/AN/A
Dr. Sandeep K. Reddy M.D.Chief Medical OfficerN/AN/AN/A
Dr. Barry J. Simon M.D.Chief Corp. Affairs Officer & DirectorN/AN/A1965
Dr. Hans Georg Klingemann M.D., Ph.D.Chief Science Officer of CellularN/AN/A1950
Ms. Helen LuuChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Corporate Governance

ImmunityBio, Inc.’s ISS Governance QualityScore as of June 30, 2022 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement